← Back to Search

Anti-tumor antibiotic

Dose Escalation Cohort 1 for Hodgkin's Lymphoma

Phase 1
Recruiting
Research Sponsored by Compass Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline until confirmed disease progression (cr or pr) (up to 2 years)
Awards & highlights

Study Summary

This trial is testing a new drug called CTX-8371 in patients with advanced cancer. The study will be done in two parts: one to find the best dose of the drug and another to

Who is the study for?
This trial is for adults with advanced cancers like breast cancer, lung cancer, or melanoma that have stopped responding to standard treatments. Participants must have tried a PD-1/PD-L1 inhibitor and, if they have a specific mutation (BRAF V600), also BRAF/MEK inhibitors.Check my eligibility
What is being tested?
The study tests CTX-8371 as a solo treatment in two parts: first finding the right dose and then seeing how well it works at that dose. It's for patients whose cancers haven't responded to other therapies.See study design
What are the potential side effects?
As this is an early-phase trial of CTX-8371, side effects are being studied; however, common side effects may include fatigue, nausea, skin reactions, or allergic responses typical of new cancer drugs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline until confirmed disease progression (cr or pr) (up to 2 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline until confirmed disease progression (cr or pr) (up to 2 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cohort 1: Determine the dose(s) of CTX-8371 to be further examined in Phase 2 studies
Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371
Cohort 2: Evaluate the safety and tolerability of CTX-8371 at dose(s) selected from Cohort 1
Secondary outcome measures
Area under the serum concentrations of CTX-8371 versus time curve (AUC) for CTX-8371
Assess the immunogenicity of CTX-8371
Clearance (CL) of serum concentrations of CTX-8371
+10 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose Expansion Cohort 2Experimental Treatment1 Intervention
Dose of CTX-8371 depending on Cohort 1 data
Group II: Dose Escalation Cohort 1Experimental Treatment1 Intervention
Escalating doses of CTX-8371

Find a Location

Who is running the clinical trial?

Compass TherapeuticsLead Sponsor
4 Previous Clinical Trials
483 Total Patients Enrolled
~37 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top